Show simple item record

dc.creatorGarcía, Leidy Y.
dc.creatorCerda, Arcadio A.
dc.date.accessioned2020-09-28T16:28:00Z
dc.date.available2020-09-28T16:28:00Z
dc.date.created2020
dc.identifier.issn0264-410Xspa
dc.identifier.otherhttps://doi.org/10.1016/j.vaccine.2020.06.068spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/13907
dc.description.abstractThe COVID-19 pandemic has not only had a negative impact on people’s health and life behavior, but also on economies around the world. At the same time, laboratories and institutions are working hard to obtain a COVID-19 vaccine, which we hope will be available soon. However, there has been no assessment of whether an individual and society value a vaccine monetarily, and what factors determine this value. Therefore, the objective of this research was to estimate the individual’s willingness to pay (WTP) for a hypothetical COVID-19 vaccine and, at the same time, find the main factors that determine this valuation. For this, we used the contingent valuation approach, in its single and double-bounded dichotomous choice format, which was based on a hypothetical market for a vaccine. The sample used was obtained through an online survey of n = 566 individuals from Chile. The main results showed that the WTP depends on the preexistence of chronic disease (p 0:05), knowledge of COVID-19 (p 0:05), being sick with COVID-19 (p 0:05), perception of government performance (p 0:01), employment status (p 0:01), income (p 0:01), health care (p 0:05), adaptation to quarantine with children at home (p 0:01Þ and whether the person has recovered from COVID-19 (p 0:10Þ. According to our discrete choice model in double-bounded dichotomous format, it was concluded that the individuals’ WTP is US$184.72 (CI: 165.52–203.92; p < 0.01). This implies a social valuation of approximately US$2232 million, corresponding to 1.09% of the GNP per capita.spa
dc.format.extent6 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherVaccinespa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectSARS-CoV-2spa
dc.subjectVaccinespa
dc.subjectAcceptancespa
dc.subjectHealth economicsspa
dc.subjectContingent valuationspa
dc.titleContingent assessment of the COVID-19 vaccinespa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1016/j.vaccine.2020.06.068spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record